SURREY, BRITISH COLUMBIA, CANADA, September 21, 2021 – Eversio Wellness Ltd. (“Eversio” or the “Company”), a mushroom wellness company, has harvested its first legal flush of psilocybin producing mushrooms under its Health Canada-issued Controlled Substances Dealer’s Licence. Psilocybin mushrooms, commonly known as magic mushrooms, contain a naturally occurring psychoactive compound, called psilocybin, involved in many clinical trials and research studies looking at its potential benefits for treating depression, post-traumatic stress disorder, addiction and withdrawal, autoimmune diseases and other brain health conditions.
In July, Eversio received its Health Canada regulatory approval to produce psilocybin for research and development, including supplying products to clinical and research trials, and to supply prescription-controlled substances to patients in need through partnerships with health care providers using Health Canada’s Special Access Program.
“Our mission is to improve lives by producing safe, standardized, natural psilocybin-based products that hold the potential to reduce suffering in many ways,” said Craig Garden, Eversio’s CEO. “Our first harvest marks a significant chapter in our company’s story as we are one step closer to bringing psychedelic mushrooms to research and healthcare communities across Canada and through global partnerships.”
“This is an important milestone for Eversio,” said Garnet Martens, Eversio’s Chief Scientific Officer. “Our diligent hard work in the lab has produced amazing results in less than two months since receiving our Controlled Substances Dealer’s Licence from Health Canada. This paves the path forward for Eversio to begin collaborative research studies in the coming months to unleash the benefits of psilocybin producing mushrooms.”
Garnet Martens oversees Eversio’s research and development activities including the cultivation of mushrooms and extraction of psilocybin. Garnet is an accomplished scientist with over 20 years of experience in research and diagnostic laboratory management. Garnet previously managed an ISO/IEC 17025:2017 laboratory, which has led to proven results with quality assurance and Canada Food Inspection Agency regulators.
Key Highlights from Eversio’s Lab:
- Creation of a custom spore library, which today includes the first sp
- Hiring of a full-time laboratory technician in August 2021 to support all lab activities;
- Purchase of state-of-the-art equipment that will arrive this fall; and
- Upcoming expansion of Eversio’s GMP compliant research and development lab.
ABOUT EVERSIO WELLNESS LTD.
Eversio is a Canadian mushroom wellness company providing high-potency, organic functional mushroom extract products and developing novel formulations with psilocybin. Eversio offers functional mushroom capsules and blends made from only the whole fruiting body of the functional mushroom life cycle. No mycelium, fillers, or grain. For more information on Eversio, visit: https://www.eversiowellness.com/.
CONTACT
Craig Garden, Co-Founder and CEO, Eversio Wellness Ltd.
craigg@eversiowellness.com
778.608.4200
FORWARD-LOOKING INFORMATION
This news release contains forward-looking information within the meaning of Canadian securities laws regarding the Company and its business, which relate to future events or future performance and reflect management’s current expectations and assumptions. Often but not always, forward-looking information can be identified by the use of words such as “expect”, “intends”, “anticipated”, “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would” or “will” be taken, occur or be achieved. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, risks regarding the Company’s ability to bring its products to commercial production, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company’s products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation.
